title: Is tailoring treatment of rectal cancer the only true benefit of long-course neoadjuvant chemoradiation?
authors.affiliation: Angelita & Joaquim Gama Institute, São Paulo, Brazil.
authors.forename: Angelita
authors.initials: A
authors.lastname: Habr-Gama
authors.forename: Joaquim
authors.initials: J
authors.lastname: Gama-Rodrigues
authors.forename: Rodrigo Oliva
authors.initials: RO
authors.lastname: Perez
mesh_terms: D059248:Chemoradiotherapy / Q000009:adverse effects / Q000379:methods; D019583:Dose Fractionation, Radiation; D006801:Humans; D008207:Lymphatic Metastasis; D020360:Neoadjuvant Therapy / Q000009:adverse effects / Q000379:methods; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D018579:Patient Selection; D011379:Prognosis; D012004:Rectal Neoplasms / Q000628:therapy*; D016896:Treatment Outcome